Cardiovascular disease (CVD) remains the biggest socio-economic burden and future threat to public health. This is largely due to an ageing population, along with increased prevalence of comorbidities and risk factors that include hypertension, type II diabetes and chronic kidney disease. There is an urgent, unmet need for new specific and effective diagnostic and prognostic indicators and therapeutic tools to treat CVD and its associated comorbidities.
RNA therapeutics is an exciting and emerging field in a number of complex disease areas. In 2018, the first RNA-based therapy was approved by the US Food and Drug Administration for cytomegalovirus retinitis. Currently, there are several RNA-based drugs in various stages of development that show promising potential for the treatment of various CVDs. Moreover, non-coding RNAs (ncRNAs) are detected in many bodily fluids, can be relatively resistant to degradation, and often reflect dynamical intracellular changes during disease progression; as such, they show potential as diagnostic and prognostic biomarkers for CVD.
In this special issue, we aim to feature articles addressing and presenting the latest advances in RNA research that emphasise the therapeutic and biomarker potential of ncRNAs in CVD. Authors are encouraged to submit novel primary research or review articles that uncover novel technical and methodological solutions in ncRNA discovery, RNA therapeutics development and delivery, as well as data from relevant animal model studies and clinical trials.
This special issue in Non-coding RNA Research is on behalf of the EU-CardioRNA COST (Cooperation in Science and Technology) Action: catalyzing transcriptomics research in cardiovascular disease. Guest editors of this SI are EU-CardioRNA members. Members and non-members alike are encouraged to submit their work to our special issue.
These will include, but not be limited to:
- RNAs in diagnosis, prognosis and therapy of cardiovascular and related disorders and comorbidities
- Recent developments in antisense oligomers, antagomirs, RNA-based therapeutic agents and RNA-targeting small molecule drugs
- Novel concepts in RNA-based drugs delivery
- Novel technical and methodological approaches in the discovery of ncRNA
- Novel strategies for quantification and normalisation of circulating ncRNAs
- Translational studies and clinical trials related to the use of RNA-based therapies and biomarkers in CVD
- Submission deadline (for full papers): 30 June 2022
- Publication date: upon acceptance
Manuscripts will be reviewed and published on a first-come, first-served basis. Once all accepted manuscripts are published, they will be gathered together in this special issue.
Dr. Emma Louise Robinson
Anschutz Medical Campus, University of Colorado, Consortium for Fibrosis Research Translation (CFReT), USA. Email: firstname.lastname@example.org
Dr. Miron Sopic
Department for Medical Biochemistry, University of Belgrade, Faculty of Pharmacy, Serbia. Email: email@example.com